No definite genetic risk factor of non-monogenic frontotemporal dementia (FTD) has yet been identified. Several groups have examined the potential association of FTD with the apolipoprotein E (APOE) gene, but the results are inconsistent. Our objective was to determine whether APOE is a risk factor of FTD, using the largest series of patients with FTD and controls analysed so far (94 unrelated patients and 392 age and sex-matched controls), and a meta-analysis. Homozygosity for the E2E2 genotype was significantly associated with FTD (odds ratio (OR)=11.3; P=0.033, exact test). After stratification on familial history (FH) for FTD, the OR for E2E2 was still found significant when analysing only patients with a positive FH (OR=23.8; P=0.019). The meta-analysis, using 10 case -control studies with available genotype or allele information, comprising a total of 364 FTD patients and 2671 controls, including the patients of the present study, did not reach statistical significance even if the E2E2 genotype was more frequent in patients than in controls (0.018 vs 0.006, respectively). Because of studies heterogeneity (Mantel-Haenszel statistics: P=0.004), we analysed on one hand the neuropathologically-confirmed studies, and on the other hand the clinical-based studies. In the neuropathologically-confirmed studies (Mantel -Haenszel statistics: P=ns), we found a significant increase of the E2 allele frequency in FTD patients (OR[E2 vs E3]=2.01; 95% CI=1.02 -3.98; P=0.04). The same result was found in the clinical-based studies, but studies heterogeneity remained. No result was significant with the E4 allele. The E2 allele
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Introduction
Frontotemporal dementia (FTD) is one of the most common cause of neurodegenerative dementia after Alzheimer's disease (AD). 1 Since the Lund and Manchester groups consensus conference in April 1994, 2 clinical and neuropathological criteria for FTD have been well established. This has lead to a better distinction of FTD from AD, which is the most frequent misdiagnosis of FTD. 3, 4 Recently, mutations in the tau gene localised to 17q21 have been identified in several families with autosomal dominant inheritance. 5 -8 To date, ten missense mutations, two deletions, and three transition mutations not altering the encoded amino-acid sequence have been identified in exons of the tau gene. 9 In addition, six intronic mutations have also been found in the 5' splice donor site of exon 10. 9,10 These mutations were detected in 25 to 40% of families with FTD that have autosomal dominant inheritance. 6, 8, 11 However, genetic heterogeneity has been demonstrated, since another locus for FTD has been mapped on chromosome 3 in a single large pedigree. 12 The genetics of non-monogenic FTD has been less studied, although several groups have examined the potential association of FTD with the apolipoprotein E (APOE) gene, with inconsistent results. 13 -26 The E4 allele of the APOE gene is now undeniably the most important risk factor in non-monogenic forms of AD. Although findings have not been as consistent as in AD, an increase in the APOE E4 allele frequency has been variably observed in other forms of dementia, including diffuse Lewy body disease 27 -29 and vascular dementia.
30,31
But it does not appear to be an important risk factor in several other neurodegenerative processes, like progressive supranuclear palsy 32 Subsequently, the results of a further study have suggested that the E2 allele, rather than the E4 allele, could be the risk factor for FTD. 15 Finally, a recent study has shown a significant increase of the E4 allele in an FTD population compared to healthy controls. 26 But ten other studies have not replicated this association. 16 -25 Because all previous studies have been based on relatively small samples (less than 35 except one study with 88 FTD patients), we have re-examined the role of APOE in a larger case -control study of 94 FTD patients and 392 controls. We performed also a meta-analysis using all published findings of similar case -control studies conducted until November 2001 to evaluate the effect of APOE as a risk factor for FTD.
Methods
Subjects All patients were ascertained over a 3-year period through consecutive admissions to 10 university hospitals in France. In this sample, we analysed the tau gene in probands with autosomal dominant inheritance by direct sequencing (exons 1 -5, 7 and 9 -14, and the corresponding flanking intronic sequences). The same mutation, P301L, was found in six patients. 8 After excluding these six patients with autosomal dominant inheritance and mutation of tau, our sample for the present study was thus composed of 94 unrelated patients with FTD (41.5% men ), laboratory tests, computed tomography and magnetic resonance imaging, regional cerebral blood flow measurement (single-photon emission computed tomography) and electroencephalography. The diagnosis of FTD was established according to the Lund-Manchester clinical consensus criteria for FTD. 2 Age at onset was assessed by interviewing a next of kin and was defined as the age at which relevant symptoms first appeared according to the family (mean+SD age at onset, 60.6+8.5 years; range, 43 -77 years). In our study, we identified 31 patients with one or more first-or second-degree relatives with FTD (33%; 35.5% men; mean+SD age at onset, 60.2+7.9 years; range, 45 -77 years), but without clear autosomal dominant inheritance and without mutation in the tau gene.
Patients with FTD were compared with 392 age-and sexmatched controls (44.9% men; mean+SD age at examination, 62.5+8.7 years; range, 38 -77 years). Control subjects were the patients' spouses or healthy blood donors or individuals living in nursing homes. None of the controls showed cognitive deficits or behavioural disturbance.
All participants in this study were white and were living in France. Informed written consent was obtained for all participants, either directly or from the legal tutor.
Meta-analysis
For the meta-analysis we searched through Medline for all studies performed for APOE in FTD until November 2001, and reviewed the references in the retrieved articles. Fourteen association studies were found. 13 -26 Two different meta-analysis were performed: one with the genotypes, and another with the alleles. For the first meta-analysis, we included only the seven studies with available information on exact genotype frequencies. 14,15,18,20,22 -24 For the second meta-analysis, three additional studies with available information on allele frequencies only were included. 13, 17, 21 Four studies could not be included in any meta-analysis because no information on exact genotype or allele frequencies was provided. 16, 19, 25, 26 In all selected studies, we have verified that the controls were in HardyWeinberg Equilibrium (HWE). 
Results

Association study
No deviation from the HWE was observed among controls. Assuming a two-sided significance level (a) of 0.05 and a power (1-b) of 80%, the size of our sample was sufficient to detect an OR of at least 1.8 when bearing the E4 allele and 2.2 when bearing the E2 allele. Genotype and allele frequencies in the control group were similar to frequencies reported in Caucasian populations ( Table 2 ). The distribution of the APOE genotypes among patients with FTD and controls was significantly different (P=0.041, exact test). We found that the E2E2 frequency was more than 10-fold higher in patients than The same analyses were performed with the E3E4 and E4E4 genotypes, and the E4 allele. None was significant.
Meta-analysis
For the meta-analysis of the APOE polymorphism in FTD, we were able to pool seven case -control studies with genotype information (total of 228 FTD patients and 2607 controls including ours), 14 We have first used the studies with available information on the genotype distribution among patients with FTD and controls. There was no significant difference between patients and controls ( Table 3 ). The E2E2 genotype was more frequent in patients than in controls but this difference failed to reach statistical significance (OR[E2E2 vs E3E3]=3.08; P=0.06, exact test). We next investigated the association with the E2 allele in the 10 selected studies (Table 3) . We found a significant increase of the E2 allele frequency in patients with FTD compared to controls (OR[E2 vs E3]=1.64; P=0.004) (Figure 1 ). But the MantelHaenszel statistics to test heterogeneity among studies was significant (P=0.004). Instead of considering one or more of the data sets as an outlier based on APOE genotype distribution and excluding it or them from the meta-analysis, we decided to reduce the heterogeneity of the meta-analysis in discriminating the studies according to the mode of recruitment (autopsy or clinic). Considering the 10 studies selected for the meta-analysis, three 22 -24 Figure 1 Meta-analysis of the E2 allele in FTD. MantelHaenszel statistics: w 2 =25.7, 10 df, P=0.004. OR: odds ratios for the E2 allele vs E3 allele. Horizontal lines represent the 95% CI for the OR. {The OR 95%CI was 1.377105.41. {The control group was the same for the two studies and was therefore included only once in the pooled control group. *No OR estimation was possible because of division by 0. The studies which were completely based on neuropathologically-confirmed patients are indicated in italics.
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Discussion
The results of our case -control study suggest that subjects who are homozygous for the APOE E2 allele are at increased risk for developing FTD. After stratification on familial history of FTD, the OR for E2E2 remains significant among patients with a positive FH (OR=23.8; P=0.019), even if the sample size is smaller (31 patients with FTD). Because E2 allele and E2E2 genotype frequencies are small in the general population (approximately 7% and 0.5% in the Caucasian population, respectively), our findings of a higher proportion of E2E2 genotype in patients compared to controls is marginally significant and predicated on very few subjects (three patients and one control). We have thus confirmed the genotype for these four subjects. Moreover, our data confirms some results of two previous studies. 13 , clinical criteria for FTD diagnosis are increasingly precise and allow to better distinguish between AD and FTD. If a significant number of patients with AD might have been inadvertently included in the first published studies, this has now become less likely. Although only a small proportion of the patients were examined neuropathologically (3%) which allowed confirmation of the diagnosis of FTD, misdiagnosis as AD in our study is un-likely given the criteria used to assess patients. Indeed, diagnosis of FTD was based on strict criteria: (a) clinical diagnosis according to the LundManchester clinical consensus criteria for FTD 2 , (b) neuropsychological confirmation of frontal lobe dysfunction, (c) frontal or frontotemporal atrophy on computed tomography or magnetic resonance images, (d) frontal or frontotemporal hypoperfusion on single-photon emission computed tomographic images and, (e) clinical and neuropsychological annual follow-up. Thirdly, studies often provide little information on case -control matching. Bickeböller et al have demonstrated that the frequency of the E4 allele was lower in males over 60 years of age than in females. 42 As the APOE allele frequency varies according to age and sex, it is crucial either to match patients and controls according to these two variables, or to take them into account by multivariate analyses.
In the meta-analysis, we examined seven case -control studies with genotype information 14,15,18,20,22 -24 and three more with allele information 13, 17, 21 (total of 364 FTD patients and 2671 controls including ours). Using genotypes, the meta-analysis did not allow to reach statistically significant level even if the E2E2 genotype was more frequent in patients than in controls. We found a significant increase of the E2 allele frequency in FTD patients compared to controls, but also a heterogeneity between the different studies. We have then performed the metaanalysis in two more 'homogeneous' groups, based on the study design: on the one hand, the studies with available data in autopsy group of patients (neuropathologicallyconfirmed studies); on the other hand, the clinical-based studies. In the first group, an overall OR was then calculated which confirmed the role of the E2 allele in these patients with an accurate diagnosis of FTD. The same result was found in the clinical-based studies. Moreover, heterogeneity disappeared in the neuropathological-based group, but remained significant in the clinical-based group, showing the importance of the mode of recruitment for patients with FTD. We have also searched for an effect of the E4 allele in the meta-analysis. Any result was significant. Since we have found that the effect of APOE E2 is more marked in patients with positive family history, it would have been interesting to study the genotype and allele distributions according to FH. Unfortunately, even if it was indicated Apolipoprotein E gene in frontotemporal dementia P Verpillat et al 403
in several previous studies, most of them did not provide enough information to stratify the meta-analysis on FH. In summary, both the genetic association study and the meta-analysis indicate that the E2 allele may be a risk factor for FTD. However, these data should be interpreted with caution because of the relatively small sample size of patients with FTD analysed and the rarity of the E2E2 genotype. As already stated by Lehmann et al in their article, 15 if this finding was confirmed, it could provide new insights to explore mechanisms of differential risk related to APOE in neurodegenerative diseases as AD and FTD.
